zinc finger protein 653Genealiases: E430039K05Rik · ZIP67
Q-omics provides the consensus-scored ZNF653 profile across patient tissues and cancer cell-line models. ZNF653 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF653 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ZNF653 RNA expression shows 19,266 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where ZNF653 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF653 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF653 survival associations across molecular data types. ZNF653 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF653 RNA expression–survival associations across cancer types. High ZNF653 expression shows unfavorable associations in ACC, KICH and COAD, but favorable associations in SCLC, KIRC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF653 RNA expression.
This table summarizes ZNF653 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF653. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF653 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, LIHC, COAD and HNSC. The KIRC box plot shows higher ZNF653 RNA expression in tumor versus normal tissue (log2 FC = +0.618, t-test p < 0.001).
This table shows molecular features associated with ZNF653 in patient tissues and cancer cell lines. In patient samples, ZNF653 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF653 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
